Peptides DB
Research-centric peptide and protocol reference hub
Study 61 of 65HCG (Human Chorionic Gonadotropin) literaturebiorxiv-preprint · Observational · Preclinical2026

SR-18292 Alters Oocyte Competence and Ovarian Transcriptomic Dynamics in Female Mice

SR-18292 increased ovulated oocytes in mice but also led to higher degeneration rates and almost no successful fertilization, indicating impaired oocyte competence.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the hcg (human chorionic gonadotropin) corpus
9
Preclinical
51
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This study investigated the effects of SR-18292 on reproductive outcomes and ovarian transcriptomic profiles in female ICR mice. The treatment resulted in increased ovulated oocytes but also a greater degeneration rate and almost no successful fertilization. The findings suggest a disruption in estrous cyclicity and impaired oocyte competence.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p>Background Mitochondria are essential for ovarian function, steroidogenesis, and oocyte development. However, the role of mitochondrial biogenesis in estrous cyclicity and oocyte competence remains incompletely understood. This study investigated the effects of SR-18292-mediated peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) inhibition on reproductive outcomes and ovarian transcriptomic profiles in female ICR mice. Methods Estrous cyclicity was monitored before, during, and after SR-18292 treatment. Oocyte yield, degeneration, and fertilization outcomes were evaluated following gonadotropin-induced superovulation and in vitro fertilization (IVF). Ovarian transcriptomes were analyzed by RNA sequencing at 48 h after pregnant mare serum gonadotropin (PMSG) and 13 h after human chorionic gonadotropin (hCG) administration, followed by differential gene expression and pathway enrichment analyses. Results SR-18292 treatment disrupted estrous cyclicity, with prolonged or stalled progression at metestrus and diestrus. Treated mice yielded significantly more ovulated oocytes following superovulation, but these oocytes exhibited a greater degeneration rate and almost no successful fertilization compared to the control group. Transcriptomic changes were more pronounced 13 h after hCG than 48 h after PMSG administration. Early transcriptomic responses were associated primarily with activated lipid metabolism, adipocytokine signaling, and hormone-related processes. Moreover, later transcriptomic responses included suppression of mitochondrial respiratory-chain and oxidative phosphorylation-associated gene categories, alongside alterations in metabolic and signaling pathways. Conclusions SR-18292 treatment was associated with disrupted estrous cyclicity, increased ovulatory output, and impaired oocyte competence. Transcriptomic analysis suggests that metabolic, hormone-responsive, and energy-sensing pathways may sustain follicular development and ovulation despite pharmacological modulation of PGC-1α, yet fail to preserve oocyte competence, revealing a potential uncoupling between ovulatory output and oocyte developmental potential. These findings support further investigation into the role of PGC-1α-associated mitochondrial regulation in female reproduction.</p>

Background

This paper addresses the role of mitochondrial biogenesis in ovarian function and oocyte competence, which remains incompletely understood. Prior research has indicated that mitochondria are essential for steroidogenesis and oocyte development. Understanding the effects of PGC-1α inhibition through SR-18292 could provide insights into reproductive health and potential therapeutic targets.

Methods

The study monitored estrous cyclicity in female ICR mice before, during, and after SR-18292 treatment. Oocyte yield, degeneration, and fertilization outcomes were evaluated following gonadotropin-induced superovulation and in vitro fertilization. Ovarian transcriptomes were analyzed by RNA sequencing at specified time points after gonadotropin administration.

Results

SR-18292 treatment disrupted estrous cyclicity, with prolonged or stalled progression at metestrus and diestrus. Treated mice yielded significantly more ovulated oocytes, but these oocytes exhibited a greater degeneration rate and almost no successful fertilization compared to controls. Transcriptomic changes were more pronounced 13 h after hCG than 48 h after PMSG.

Interpretation

The findings indicate a significant effect of SR-18292 on oocyte yield and quality, with a notable disconnect between ovulatory output and oocyte competence. While the results are statistically significant, the clinical implications remain uncertain due to the small sample size and rodent model. Further research is needed to explore the role of mitochondrial regulation in female reproduction.

Key findings

  • Treated mice yielded significantly more ovulated oocytes following superovulation, but exhibited a greater degeneration rate.
  • Almost no successful fertilization compared to the control group.
  • Transcriptomic changes were more pronounced 13 h after hCG than 48 h after PMSG administration.
  • Early transcriptomic responses were associated primarily with activated lipid metabolism and hormone-related processes.
  • Later transcriptomic responses included suppression of mitochondrial respiratory-chain and oxidative phosphorylation-associated gene categories.

Limitations

  • rodent only, no human data
  • small sample size not specified
  • single treatment without long-term follow-up
  • no assessment of clinical outcomes

Elsewhere in the HCG (Human Chorionic Gonadotropin) corpus

BEarly pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma.Seminars in oncology · 2026 · n=1 · Not reported in abstract.HumanBEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2024 · n=177 · Treatment success occurred in 94 of 177 women (53.1%).HumanBSuccessful fertility-preserving management of a viable cesarean scar ectopic pregnancy: a case report.Case reports in women's health · 2026 · n=1 · Estimated blood loss of 20 mL.HumanBEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · 53.1% treatment success in 177 women.HumanBHigh-grade endometrioid carcinoma arising from uterine serosal endometriosis with focal choriocarcinomatous differentiation and embryonal carcinoma-like morphology: a case report and literature reviewbiorxiv-preprint · 2023 · n=1 · Serum β-hCG remained persistently below 1 mIU/mL throughout follow-up.HumanBEfficacy of hysteroscopic curettage and niche resection in type II and III cesarean scar pregnancies.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2026 · n=105 · 20 (15,25) min vs 25 (20,31) min operation time, p=0.001Human